Who is sponsoring NCT04779788?

NCT04779788 is sponsored by Xuzhou Central Hospital.

What drugs are being tested in NCT04779788?

Interventions in NCT04779788: I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China), Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China).

What condition does NCT04779788 study?

NCT04779788 studies Hilar Cholangiocarcinoma.

Is NCT04779788 still recruiting?

NCT04779788 is currently status unknown. Last updated 14 July 2021.

Last reviewed 2021-07-14 · How we verify

NCT04779788

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma

Status unknown NA Last updated 14 July 2021

What this trial tests

NA trial testing I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China) in Hilar Cholangiocarcinoma in 100 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
31 December 2021

30 June 2022

Quick facts

Lead sponsor	Xuzhou Central Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 April 2021
Primary completion	31 December 2021
Estimated completion	30 June 2022
Sites	1 location across China

Drugs / interventions tested

I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China)
Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)

Conditions studied

Hilar Cholangiocarcinoma — all drugs for Hilar Cholangiocarcinoma →

Sponsor

Xuzhou Central Hospital

Who can join

Adults 18 to 80, any sex, with Hilar Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such palliative stent insertion is the only treatment option available for most patients. At present, I-125 seeds loaded stent has been developed to improve the stent patency and patients' survival. Hilar malignant biliary obstruction is an important part of malignant biliary obstruction. Hilar cholangiocarcinoma is the most common disease which causes hilar malignant biliary obstruction. Herein, we assessed the clinical and long-term efficacy of I-125 seeds loaded stent insertion for hilar cholangiocarcinoma patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radioactive stent insertion for inoperable hilar cholangiocarcinoma: a prospective randomized controlled trial.
Song T, Feng AQ, Fu YF, Cao C, et al · · 2023 · cited 4× · PMID 37680729 · DOI 10.5114/wiitm.2022.123312

Verify or expand the search:

Other recruiting trials for Hilar Cholangiocarcinoma

Currently open trials in the same condition.

NCT06717464 — Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepa · Phase 2 · active not recruiting
NCT07176962 — A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening · recruiting

Other Xuzhou Central Hospital trials

Trials by the same sponsor.

NCT06126289 — CSF Single-cell Sequencing and Proteomics of Chronic Postsurgical Pain in Patients With Lower Limb Fractures · unknown
NCT06136663 — Prevalence and Risk Factors for Postsurgical Pain After the Open Reduction and Internal Fixation of Lower Limbs. · unknown
NCT06050096 — DCB Treatment in CTO Guided by IVUS · unknown
NCT06395961 — Effect of New High Ankle Block on Wound Healing After the Operation of Debridement of Diabetes Foot · NA · enrolling by invitation
NCT05772026 — Plasma Proteomics in Patients With Postoperative Delirium · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04779788 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xuzhou Central Hospital
Last refreshed: 14 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04779788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing